W
WAVEMAN · COMPANY
EXOZ · Exozymes Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

EXOZ

EXOZYMES INC.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0002010788
C-SUITE BUYING · 1☆ WATCH
INSIDER NET · 180D
-$9.0K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
7
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
2
codes C/M, not in net · no price filed
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$9.0K over 180 days
+$6.4K over 90 days
more than 63% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
7 funds added or opened last quarter
below 91% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
0.2% of shares outstanding short · 2.6 days to cover · settled 2026-07-31
below 84% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -29.3%
-29.3%12M
-55%-13%+29%+70%2025-092025-102025-122026-032026-052026-072026-09 2026-04-09 · Korman Tyler Paz sold $7.9K2026-04-08 · Korman Tyler Paz sold $7.5K2026-08-26 · Heltzen Michael bought $1.9K2026-08-25 · Heltzen Michael bought $1.9K2026-08-26 · Heltzen Michael bought $1.8K2026-08-25 · Heltzen Michael bought $7502026-08-26 · Heltzen Michael bought $30
INSIDER BUYINSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows a net $9.0K sold by insiders over 180 days, 7 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, EXOZYMES INC. insiders sold a net $9.0K of stock across 8 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Heltzen Michael
Chief Executive Officer
BUY
2026-08-26
4.0
$30
Heltzen Michael
Chief Executive Officer
BUY
2026-08-26
251.0
$1.8K
Heltzen Michael
Chief Executive Officer
BUY
2026-08-26
250.0
$1.9K
Heltzen Michael
Chief Executive Officer
BUY
2026-08-25
250.0
$1.9K
Heltzen Michael
Chief Executive Officer
BUY
2026-08-25
100.0
$750
8 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 3 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
VANGUARD CAPITAL MANAGEMENT LLC
54,985.0 sh
$463.5K
Davidson Kahn Capital Management, LLC
25,000.0 sh
$210.8K
GEODE CAPITAL MANAGEMENT, LLC
23,406.0 sh
$197.3K
BlackRock, Inc.
9,610.0 sh
$81.0K
VANGUARD FIDUCIARY TRUST CO
9,426.0 sh
$79.5K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
iShares Micro-Cap ETF
$48.0K POSITION · AS OF 2026-03-31
0.0%
1290 VT Micro Cap Portfolio
$3.3K POSITION · AS OF 2026-03-31
0.0%
Victory Extended Market Index Fund
$2.5K POSITION · AS OF 2026-04-30
0.0%
Fidelity Extended Market Index Fund
$107.0K POSITION · AS OF 2026-02-28
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$163.5K POSITION · AS OF 2026-03-31
0.0%
Fidelity Nasdaq Composite Index Fund
$17.0K POSITION · AS OF 2026-02-28
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-12
REVENUE$70.1K
OPERATING INCOME$-9.7M$-5.9M$-1.8M
NET INCOME$-9.2M$-5.9M$-2.0M
EPS (DILUTED)-1.09-0.89-0.33
OPERATING CASH FLOW$-6.5M$-8.5M$-1.2M
CASH$3.0M$9.7M$66.5K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →